Delix Therapeutics Closes $30 - GuruFocus.com
GuruFocus Article or News written by PRNewswire and the topic is about:
Source: gurufocus.com
📰 Mark Rus News
Page 2 - Mark Rus News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Rus. Real-time updates on events, politics, business and more.
Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders
/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological...
United States Mark Rus Abby Berger Davide Olson Strategic Communications National Institute On Drug Abuse
Source: prnewswire.com
Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders
/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological...
United States Mark Rus Abby Berger Davide Olson Strategic Communications National Institute On Drug Abuse
Source: prnewswire.com
Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board
/PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and...
Source: prnewswire.com
Delix Therapeutics Named One of Fierce Biotech's "Fierce 15" Companies of 2021
/PRNewswire/ -- Delix Therapeutics (the "Company") is honored to have been named by Fierce Biotech as one of 2021s "Fierce 15" biotechnology companies,...
Source: prnewswire.com
Delix Therapeutics Announces Scientific & Strategic Advisory Board Appointments
/PRNewswire/ -- Delix Therapeutics (the "Company"), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric...
Source: prnewswire.com
Delix Therapeutics Retains KCSA Strategic Communications
Delix Therapeutics Retains KCSA Strategic Communications KCSA to provide integrated public and investor relations counsel News provided by Share this article Share this article BOSTON, May 19, 2021 /PRNewswire/ -- Delix Therapeutics (the "Company"), a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced that it has retained KCSA Strategic Communications, a leading integrated communications firm, as its a...
United States Lewis Goldberg Mark Rus Davide Olson Department Of Chemistry At University California Strategic Communications
Source: prnewswire.com
Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a Psychedelic Analog--Without Hallucinogenic Effects
Share: BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University of California, Davis, reveals ...
Source: benzinga.com
Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a Psychedelic Analog--Without Hallucinogenic Effects
Share this article Share this article BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer, Professor David E. Olson, PhD. The paper, co-authored by Olson and collaborator Lin Tian, PhD, both of whom are professors at the University...
Source: prnewswire.com